measurement of antibiotica concentration in blood and subcutis in patients treated with crrt

Concentration of piperacillin in plasma and subcutis in patients on crrt treatment

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-000717-24-DK

Enrollment

Registered

2017-02-22

Start date

2017-08-24

Completion date

Unknown

Last updated

2021-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infections reloated to CRRT MedDRA version: 20.0 Level: LLT Classification code 10021804 Term: Infection bacterial System Organ Class: 100000019640 MedDRA version: 20.0 Level: LLT Classification code 10021863 Term: Infection respiratory System Organ Class: 100000015677 MedDRA version: 20.0 Level: LLT Classification code 10021867 Term: Infection systemic System Organ Class: 100000165071

Interventions

Trade Name: piperacillin/tazobactam Product Name: piperecillin/tazobactam Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: piperacillin Other descriptive name: P

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: informed consent age>18 piperacillin treatment CRRT sedation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria: pregancy lack of consent allergy to piperacillin

Design outcomes

Primary

Measure	Time frame
Main Objective: to measure concentration of piperacillin/tazobactam in subcutisw and blood in patients on crrt;Secondary Objective: na;Primary end point(s): time above MIC during dosage interval in plasma and subcutis;Timepoint(s) of evaluation of this end point: at the end of the study	—

Secondary

Measure	Time frame
Secondary end point(s): pharmacokinetics ( Cmax, Tmax, Vd);Timepoint(s) of evaluation of this end point: at the end of the study	—

Countries

Denmark

Contacts

Public ContactAnna Sophie Okkels

Aarhus University Hospital

asokkels@hotmail.com

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026